Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow INDV
Indivior Pharmaceuticals Inc. (INDV) Altman Z-score
Indivior Pharmaceuticals Inc.'s Altman Z-score for fiscal 2025 is 3.28, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.28 | 2.24 |
| FY2024 | 1.03 | 0.32 |
| FY2023 | 0.72 | (1.88) |
| FY2022 | 2.60 | (0.66) |
| FY2021 | 3.26 | 1.07 |
| FY2020 | 2.19 | (0.47) |
| FY2019 | 2.67 | (0.59) |
| FY2018 | 3.26 | (0.69) |
| FY2017 | 3.95 | 0.59 |
| FY2016 | 3.36 | (1.50) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.22) | — | −0.26 | |
| Retained earnings / total assets | (0.20) | — | −0.28 | |
| EBIT / total assets | 0.22 | — | 0.72 | |
| Market value of equity / total liabilities | 3.45 | — | 2.07 | |
| Sales / total assets | 1.03 | — | 1.03 | |
| Altman Z-score | Safe zone | 3.28 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −0.70 | ||
Z and Z″ put Indivior Pharmaceuticals Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 10.4× |
| ALKS Alkermes plc compare | 5.3× |
| LNTH Lantheus Holdings, Inc. compare | 4.3× |
| LQDA Liquidia Corporation compare | 4.1× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 3.5× |
| INDV Indivior Pharmaceuticals Inc. | 3.3× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 1.9× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −2.9× |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets